BAIT
CBL
C-CBL, CBL2, FRA11B, NSLL, RNF55
Cbl proto-oncogene, E3 ubiquitin protein ligase
GO Process (10)
GO Function (5)
GO Component (4)
Gene Ontology Biological Process
- cell surface receptor signaling pathway [TAS]
- epidermal growth factor receptor signaling pathway [TAS]
- fibroblast growth factor receptor signaling pathway [TAS]
- negative regulation of apoptotic process [IMP]
- negative regulation of epidermal growth factor receptor signaling pathway [TAS]
- positive regulation of phosphatidylinositol 3-kinase signaling [IMP]
- positive regulation of receptor-mediated endocytosis [TAS]
- protein ubiquitination [TAS]
- regulation of transcription, DNA-templated [TAS]
- transforming growth factor beta receptor signaling pathway [TAS]
Gene Ontology Molecular Function
Gene Ontology Cellular Component
Homo sapiens
PREY
GNAI2
GIP, GNAI2B, H_LUCA15.1, H_LUCA16.1
guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 2
GO Process (11)
GO Function (5)
GO Component (9)
Gene Ontology Biological Process
- G-protein coupled receptor signaling pathway [TAS]
- adenosine receptor signaling pathway [IBA]
- adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway [IBA, TAS]
- blood coagulation [TAS]
- cell division [IMP]
- gamma-aminobutyric acid signaling pathway [IBA]
- negative regulation of adenylate cyclase activity [TAS]
- platelet activation [TAS]
- response to nutrient [TAS]
- signal transduction [TAS]
- synaptic transmission [TAS]
Gene Ontology Molecular Function
Gene Ontology Cellular Component
Homo sapiens
Affinity Capture-MS
An interaction is inferred when a bait protein is affinity captured from cell extracts by either polyclonal antibody or epitope tag and the associated interaction partner is identified by mass spectrometric methods.
Publication
CBL mutations drive PI3K/AKT signaling via increased interaction with LYN and PIK3R1.
Casitas B-lineage lymphoma (CBL) encodes an E3 ubiquitin ligase and signaling adaptor that regulates receptor and nonreceptor tyrosine kinases. Recurrent CBL mutations occur in myeloid neoplasms, including 10% to 20% of chronic myelomonocytic leukemia (CMML) cases, and selectively disrupt the protein's E3 ubiquitin ligase activity. CBL mutations have been associated with poor prognosis, but the oncogenic mechanisms and therapeutic implications ... [more]
Blood Dec. 22, 2020; 137(16);2209-2220 [Pubmed: 33512474]
Throughput
- Low Throughput
Curated By
- BioGRID